Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
02/10/2026 07:34
BRIEF-Jcr Pharmaceuticals Co., Ltd. - Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America Oct 2 (Reuters) - JCR Pharmaceuticals Co., Ltd. 4552.T:
JCR PHARMACEUTICALS CO., LTD.: ITALFARMACO AND JCR PHARMACEUTICALS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR JR-141 IN UNITED STATES, EUROPE, AND LATIN AMERICA
JCR PHARMACEUTICALS CO., LTD.: ITALFARMACO S.P.A. AND JCR SIGN EXCLUSIVE LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE JR-141 IN US, EUROPE, AND LATIN AMERICA UPON REGULATORY APPROVAL
JCR PHARMACEUTICALS CO., LTD.: JCR WILL RECEIVE UPFRONT, MILESTONE AND ROYALTY PAYMENTS, IN ADDITION TO REVENUES ASSOCIATED WITH PRODUCT SUPPLY
Source text: ID:nTSvb851d5
Further company coverage: 4552.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results